20 Years Advancing NICU Nutrition and Improving Outcomes for Babies Under 3 Pounds
20 Years Advancing NICU Nutrition and Improving Outcomes for Babies Under 3 Pounds
DUARTE, Calif., Sept. 2, 2026
Prolacta Marks NICU Awareness Month, Celebrating Two Decades Bringing100% Breastmilk-Based Fortifiers & Formulas to NICUs Nationwide
DUARTE, Calif., Sept. 2, 2026 /PRNewswire/ — Prolacta Bioscience® is marking NICU Awareness Month and 20 years of providing 100% human breastmilk-based fortifiers and formulas, free from cow milk, for babies born under 3 pounds. Since introducing Prolact+ H2MF® in 2006, Prolacta has helped improve outcomes by changing how neonatal intensive care units (NICUs) feed the smallest premature infants, those weighing 2.75 pounds or less (<1250 g)
Supporting Growth in the Smallest Premature InfantsExtremely premature babies need significantly more calories, protein, and nutrients than full-term babies to catch up on the growth they didn’t receive in the womb. This is why doctors often add a nutritional “fortifier” to mom’s breastmilk or donor milk for the smallest preemies. These fortifiers provide the extra nutrition necessary for healthy growth and development.
There are two types of fortifiers available in the NICU: one made from cow milk, and one made from donor breastmilk. In the U.S., both are labeled “human milk fortifiers,” which can be confusing for parents and clinicians alike. However, only those from Prolacta are 100% donor breastmilk-based, free from cow milk and corn syrup ingredients.
How Early NICU Nutrition Can Shape Long-Term DevelopmentWhat preemies are fed in the NICU doesn’t just matter today; it impacts tomorrow’s developmental milestones. A recent study followed more than 1,000 premature babies from birth through age 3 to examine how their early nutrition affected their development.1 Babies fed an Exclusive Human Milk Diet (EHMD) including breastmilk and Prolacta’s human milk-based fortifiers were significantly less likely to have motor skill delays at age 3 compared to those fed a non-EHMD. These motor skills help toddlers walk, run, climb, and explore their world, along with other children their same age.
The positive health outcomes go beyond motor skills. Earlier <a href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4765381-1&h=4192908541&u=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41372-022-01513-3&a=research” rel=”nofollow noopener” target=”_blank”>research showed that an exclusive human milk diet also leads to significantly higher cognitive scores (thinking, learning, attention) at 18-22 months.2 Together, these studies reveal that the feeding choices parents and care teams make in the NICU can shape a child’s development for years to come.
“For 20 years, Prolacta has provided a clinically proven alternative to cow milk-based fortifiers, supporting improved outcomes for the smallest, most vulnerable premature infants,” said Scott Elster, CEO of Prolacta. “With quality and safety at the center of everything we do, we’re gratified to help these babies go home sooner and continue to thrive as they grow and develop.”
About Prolacta BioscienceProlacta Bioscience® is the global leader in human milk-based nutrition, dedicated to improving health outcomes for critically ill and premature infants. More than 125,000 vulnerable infants worldwide have benefited from Prolacta’s human milk-based fortifiers and formulas since 2006.3 In a global first, Japan granted prescription drug status to Prolacta’s PreemieFort® fortifiers in late 2025 for very low birth weight infants, infants with congenital gastrointestinal disorders or congenital heart disease, and those recovering from gastrointestinal surgery at risk for poor growth. Prolacta adheres to the industry’s strictest quality and safety standards, operating pharmaceutical processing facilities and applying more than 20 donor milk screening tests. Its use of vat pasteurization inactivates pathogens while keeping human milk closer to its natural state than other human milk processing methods, preserving the bioactive components of human milk that support immune protection, brain development, and growth in premature and medically fragile infants.4-6 Prolacta’s products have been evaluated in over 30 peer-reviewed clinical studies, demonstrating the short- and long-term health benefits of its patented human milk-based fortifiers and formulas. Learn more online or at X, Instagram, Facebook, TikTok, and LinkedIn.
Media Contact:Loren KosmontLkosmont@prolacta.com
References | |
1. | Chou FS, Zhang J, Villosis MFB, Lakshmanan A. Exclusive human milk diet is associated with lower risk of motor function impairment at three years of corrected age. J Perinatol. 2025;45(9):1274-1280. doi:10.1038/s41372-025-02296-z |
2. | Hair AB, Patel AL, Kiechl-Kohlendorfer U, et al. Neurodevelopmental outcomes of extremely preterm infants fed an exclusive human milk-based diet versus a mixed human milk + bovine milk-based diet: a multi-center study. J Perinatol. 2022;42(11):1485-1488. doi:10.1038/s41372-022-01513-3 |
3. | Data on file; estimated number of premature infants fed Prolacta’s products from January 2007 to May 2025 |
4. | Ozturk G, Pa, size, and functionality after thermal processing and homogenization of human milk. Foods. 2024;13(8):1242. doi:10.3390/foods13081242 |
5. | Liang N, Koh J, Kim BJ, Ozturk G, Barile D, Dallas DC. Structural and functional changes of bioactive proteins in donor human milk treated by vat-pasteurization, retort sterilization, ultra-high-temperature sterilization, freeze-thawing and homogenization [published correction appears in Front Nutr. 2024;11:1371799]. Front Nutr. 2022;9:926814. doi:10.3389/fnut.2022.926814 |
6. | Meredith-Dennis L, Xu G, Goonatilleke E, Lebrilla CB, Underwood MA, Smilowitz JT. Composition and variation of macronutrients, immune proteins, and human milk oligosaccharides in human milk from nonprofit and commercial milk banks. J Hum Lact. 2018;34(1):120-129. doi:10.1177/0890334417710635 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/20-years-advancing-nicu-nutrition-and-improving-outcomes-for-babies-under-3-pounds-302866984.html
SOURCE Prolacta Bioscience
The articles, information, and content displayed on this webpage may
include materials prepared and provided by third parties. Such
third-party content is offered for informational purposes only and
is not endorsed, reviewed, or verified by Morningstar
Morningstar makes no representations or warranties regarding the
accuracy, completeness, timeliness, or reliability of any third-party
content displayed on this site. The views and opinions expressed in
third-party content are those of the respective authors and do not
necessarily reflect the views of Morningstar, its affiliates, or employees
Morningstar is not responsible for any errors, omissions, or delays
in this content, nor for any actions taken in reliance thereon.
Users are advised to exercise their own judgment and seek independent
financial advice before making any decisions based on such content.
The third-party providers of this content are not affiliated with
Morningstar, and their inclusion on this site does not imply any
form of partnership, agency, or endorsement
We’re more optimistic about this stock now than we’ve been in a long time.
David Whiston, CFA, CPA, CFEAug 27, 2026
Plus, whether Nvidia, Marvell Technology, or Salesforce looks attractive after earnings.
David Sekera, CFA and Susan DziubinskiAug 31, 2026
Top investors have been selling these stocks recently.
Susan DziubinskiAug 26, 2026
Plus, tips to leverage the SALT deduction and prevent leaving behind a big tax bill.
Sheryl Rowling and Ivanna HamptonAug 28, 2026
Why a fan of ‘good enough’ investing isn’t losing sleep over these often-criticized financial moves.
Christine BenzAug 31, 2026
